Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
News|Articles|October 29, 2019
SEA Vision to Present Latest Developments and Solutions at CPhI Worldwide 2019
Author(s)Pharmaceutical Technology Editors
The company will be exhibiting several solutions and innovations including its HarleNIR vision system, Yudoo software suite, and Ubiquity software.
Advertisement
SEA Vision, an Italy-based vision systems supplier, announced it will showcase its latest developments and solutions at P-MEC Europe, a part of CPhI Worldwide, from Nov. 5–7, 2019 in Frankfurt, Germany.
According to an Oct. 28, 2019 press release, the company will be exhibiting several solutions and innovations including:
- HarleNIR, a vision system that can carry out qualitative analyses on solid products with a hyperspectral camera while rejecting defective products. The device is non-destructive, shortens batch release times, and prevents the risk of mixing up tablets.
- Yudoo, a software suite that incorporates additional 4.0 applications to redesign the concept of line management for the pharmaceutical sector. The suite also includes centralized control systems, key performance indicators on historical data, data historicization, OEE Tools, real-time dashboards, integrated Track & Trace functions, and predictive maintenance.
- Ubiquity, a software that gives the SEA Vision service team access to the homeless management information systems of any vision system installed on the packaging lines to offer operators timely remote support.
SEA Vision will be located in hall 11.0 at stand D60 at the event.
Source:
Advertisement
Related to this article
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Advertisement
Advertisement